trending Market Intelligence /marketintelligence/en/news-insights/trending/TUDOYqXgxnf3_mGEVd3BHg2 content esgSubNav
In This List

GLG Pharma Q1 loss narrows YOY

Case Study

Broad Environmental Data Guides an Insurer’s Journey to Net Zero

Blog

Broadcast deal market recap, Q2'22

Blog

Japan M&A By the Numbers: Q1 2022

Podcast

Next in Tech | Episode 77: Language in Tech


GLG Pharma Q1 loss narrows YOY

GLG Pharma S.A. said its normalized net income for the first quarter came to a loss of 7,440 zlotys, compared with a loss of 15,440 zlotys in the year-earlier period.

Normalized net income excludes unusual gains or losses on a pre- and after-tax basis.

Reported net income totaled a loss of 11,900 zlotys, or a loss of 0 groszy per share, compared to a loss of 24,700 zlotys, or a loss of 3 groszy per share, in the prior-year period.

As of May 17, US$1 was equivalent to 3.86 zlotys.